Study results of two investigational drugs that target KRAS-driven cancers co-developed by RAS Initiative investigators at the Frederick National Laboratory for Cancer Research (FNL) and now being tested in patients will be presented at the American Association for Cancer Research Annual Meeting April 25-30 at McCormick Place in Chicago. Both…